Treatment for HH is typically indicated for iron overload in symptomatic patients. The goal of therapy is to reduce stored iron, which may result in reversal or resolution of some symptoms and improve prognosis.
Physicians may choose to monitor the clinical status of asymptomatic patients with HH or those with modestly elevated ferritin levels. If ferritin increases or symptoms appear, treatment can be undertaken.
Causes of death in patients with HH include serious medical conditions such as hepatocellular carcinoma, cirrhosis, cardiomyopathy, and diabetes. Ideally, treatment should begin before these conditions develop. The earlier HH is detected, before the onset of severe organ damage, the lower the mortality risk.
